Skip to main content

Advertisement

Table 2 Overall survival according to characteristics (n = 103)

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic Median OS 95% CI 3-year
survival
rate (%)
P-value
Age <60
≥ 60
32.0
27.0
20.9-43.1
12.6-41.4
44.2
31.0
.053
Sex Male
Female
29.0
31.0
20.5-37.5
26.7-35.3
36.4
42.9
.461
Carcinoid symptom Absent
Present
29.0
28.0
23.3-34.7
23.7-32.3
40.5
-
.646
  Pancreas 43.0 23.4-62.6 45.3  
Origin GI 40.0 10.3-69.7 51.2 .660
  Lung 10.0 - -  
Liver metastasis Absent
Present
29.0
29.0
18.6-39.4
22.8-35.2
42.2
38.1
.995
  1 78.0 32.3-123.7 65.8  
Grade 2-3 18.0 1.9-34.1 29.8 .001
  Large 15.0 2.8-27.2 13.9  
  Small 18.0 7.1-28.9 17.9  
  24-hour urine 5-HIAA (μmol/day) <31.4 31.0 24.3-37.7 42.8 .653
   ≥ 31.4 46.0 - 66,7  
Biomarkers       
  Serum NSE (nmol/l) <1.0 31.0 - 47.7 .051
   ≥ 1.0 7.0 4.3-9.7 26.8  
  Local treatment only 43.0 23.1-62.9 53.0  
Treatment modality Systemic treatment only 23.0 0.4-45.6 38.0 .245
  Both treatments 29.0 23.6-34.4 43.0  
  1. OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase